Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox).
Michael O'Connell
No relevant relationships to disclose
Mark Lee
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Margarita Lopatin
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Greg Yothers
No relevant relationships to disclose
Kim Clark-Langone
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Carl Millward
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Soonmyung Paik
No relevant relationships to disclose
Saima Sharif
No relevant relationships to disclose
Steven Shak
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Norman Wolmark
No relevant relationships to disclose